Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid-Guided Therapy in Drug-Resistant Lung Cancer
NCT05669586Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Feb 2023
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Progression-free survival at 1 year. Started Feb 2023; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05669586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669586.